PureTech Health (GB:PRTC) has released an update.
PureTech Health plc, a clinical-stage biotherapeutics company, announced the full vesting of restricted share units granted to its non-executive directors as part of its Performance Share Plan. Following the vesting, the company’s total issued share capital increased, with new ordinary shares distributed among the directors at a nominal price. PureTech’s extensive R&D efforts have led to the development of 29 therapeutic candidates, two of which have been approved by regulators, underscoring the company’s commitment to innovative medicine.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
